Alzheimer’s drugs Market - Global Industry Analysis

Table Of Content

Methodology

Free Analysis

Alzheimer's disease is a type of dementia which includes a broad group of brain diseases, such as problems with memory, thinking, and behavior for long term. Causes of Alzheimer’s diseases are still unknown. Alzheimer’s symptoms usually grow slowly and get worse over time. It becomes severe, enough to obstruct a patient’s daily activity. Many researchers consider increasing level of a protein called amyloid in the brain as one of the major causes of Alzheimer disease. It may cause the death of the nerve cells. Major risk factor for Alzheimer disease is growing age wherein people aged 65 and older majorly tend to suffer from Alzheimer disease. Additionally, there are also some genetic and some other causes of Alzheimer diseases. At this moment there is no treatment which can stop the growth of the Alzheimer’s disease. But scientist and researchers are working continuously on it. 

According to Center of Disease Control and Prevention (CDC), in 2017 near about 5.5 million Americans were suffering from Alzheimer’s diseases. Alzheimer is considered as the fifth leading cause of death for all adults. The market is mainly driven by the growing occurrence of diseases in developed countries specifically in the Western region. Also, the prevalence of some neurodegenerative diseases such as dementia has grown in the U.S. In addition, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development and growing alertness about the treatment of Alzheimer ’s disease is resulting into increased demand for Alzheimer’s drugs market. Furthermore, growing support for psychological care infrastructure from governments in several developing Asia Pacific countries is likely to drive the Alzheimer's drugs market. However, high prices of the advance drugs may create restraints in underdeveloped countries. Awareness about Alzheimer’s disease in developing regions remains restricted that has resulted in unbalanced healthcare systems and obstructive research infrastructure. In Asia Pacific region, growing encouragement for mental care by governments is anticipated to drive the Alzheimer's drugs market in the near future.

The Alzheimer’s drugs market is classified based on drug class, distribution channel, and region. On the basis of drug class, the market is divided into, memantine, cholinergic, and combined drug. Memantine drug-dominated the global Alzheimer’s drugs market in 2017 due to the large range expiry of patents of key products and a limited number of medicines to treat Alzheimer’s disease. Memantine drug segment is anticipated to lead the market in the forecast period. Owing to the inadequate availability of the productive drug classes all over the globe, the cholinergic segment is also estimated to contribute primarily to the overall market share of the global market for Alzheimer’s drug market. And it is predicted to expand at a moderate growth rate over the forecast period. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online sales.
 
Demand for Alzheimer’s drug is growing worldwide, with North America and Europe contributing majorly to the Alzheimer’s drug market. North America dominated the Alzheimer’s drug market in 2017 due to the growing occurrence of disease in this region. This region will continue to remain the principal segment for Alzheimer's drugs market in the future. 

The Asia Pacific is the highest growing market and is expected to remain the same in the coming future. Due to growing awareness of Alzheimer’s treatment in the Asia Pacific region, this region is a key contributor to the global Alzheimer's drugs market in the coming years. Latin America is another key geographical market and is likely to have a moderate growth in the future due to developing healthcare infrastructure and rising awareness. The Middle East and Africa region are anticipated to witness significant growth within the forecast period. 
Some of the key players in Alzheimer’s drugs market include Ono Pharmaceutical, Johnson & Johnson, Daiichi Sankyo Company Limited, H Lundbeck A/S, and Eisai Co. Ltd., among others.